CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO
CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO
VANCOUVER, Washington, Dec. 23, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, will hold a webcast on December 29, 2022 at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time) to discuss the performance of leronlimab in its clinical trials and the recent charges against its former CEO Nader Pourhassan, who was previously terminated on January 24, 2022, and has had no affiliation with the Company since that time.
溫哥華市，華盛頓，2022 年 12 月 23 日（環球美通社）-- 賽托加因股份有限公司 (OTCQB: 賽迪) 開發具有多種治療適應症潛力的 CCR5 拮抗劑萊隆利單抗的生物技術公司（「CytoDyn」或「公司」）將於 2022 年 12 月 29 日上午 8 點（東部時間上午 11 點）舉行網絡直播，討論萊龍利瑪在其臨床試驗中的表現以及最近針對其前首席執行官 Nouran Passader 被終止的指控 2022 年 1 月 24 日，自那時起與本公司並無任何關係。
Webcast Access Information
網路廣播存取資訊
| Date: | Thursday, December 29, 2022 |
| Time: | 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time |
| Access: |
| 日期: | 二 ○ 二二二年十二月二十九日 |
| 時間: | 太平洋時間上午 8 點 00 分/美國東部時間上午 11 點 |
| 存取： |
The replay will be available approximately 60 minutes after the conclusion of the webcast and can be accessed via the above link until January 29, 2023.
重播將於網路廣播結束後約 60 分鐘開放，並可透過上述連結觀看，直到 2023 年 1 月 29 日為止。
About CytoDyn
CytoDyn is a clinical-stage biotechnology company focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells that is believed to play a role in numerous disease processes. CytoDyn is studying leronlimab in multiple therapeutic areas, including infectious disease, cancer, and autoimmune conditions.
關於賽托達因
CytodyN 是一家臨床階段的生物技術公司，專注於來龍利單抗（Leronlimab）的開發和商業化，這是一種研究人性化 Ig4 單克隆抗體（MaB），旨在與 C-C 化莫金受體 5（CCR5）結合，這是一種在許多疾病過程中發揮作用的蛋白質。CytodyN 正在研究萊諾利單抗在多個治療領域，包括傳染病，癌症和自身免疫性疾病。
CONTACTS
Investors:
Cristina De Leon
Office: 360.980.8524
ir@cytodyn.com
連絡人
投資者：
克里斯蒂娜·德莱昂
辦公室:
ir@cytodyn.com
Media:
Greg Salsburg
STiR Communications
info@stir-communications.com
媒體:
格雷格·萨尔斯堡
攪拌通訊
info@stir-communications.com
譯文內容由第三人軟體翻譯。